ArcticZymes Technologies ASA (FRA:B4V) Long-Term Capital Lease Obligation : €0.44 Mil (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is ArcticZymes Technologies ASA Long-Term Capital Lease Obligation?

ArcticZymes Technologies ASA's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2024 was €0.44 Mil.

ArcticZymes Technologies ASA's quarterly Long-Term Capital Lease Obligation declined from Mar. 2024 (€0.60 Mil) to Jun. 2024 (€0.53 Mil) and declined from Jun. 2024 (€0.53 Mil) to Sep. 2024 (€0.44 Mil).

ArcticZymes Technologies ASA's annual Long-Term Capital Lease Obligation declined from Dec. 2021 (€1.43 Mil) to Dec. 2022 (€0.99 Mil) and declined from Dec. 2022 (€0.99 Mil) to Dec. 2023 (€0.73 Mil).

ArcticZymes Technologies ASA Long-Term Capital Lease Obligation Historical Data

The historical data trend for ArcticZymes Technologies ASA's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArcticZymes Technologies ASA Long-Term Capital Lease Obligation Chart

ArcticZymes Technologies ASA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

1.27

0.91

1.43

0.99

0.73

ArcticZymes Technologies ASA Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.82	0.73	0.60	0.53	0.44

ArcticZymes Technologies ASA (FRA:B4V) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

ArcticZymes Technologies ASA Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of ArcticZymes Technologies ASA's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

ArcticZymes Technologies ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArcticZymes Technologies ASA (FRA:B4V) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

BIOTECO:Sweden AZT:Norway 0DRV:UK B4V:Germany

Address

Sykehusveien 23, Tromso, NOR, 9294

Website

https://www.arcticzymes.com

ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Germany, Italy, France, and other countries.

ArcticZymes Technologies ASA Headlines

No Headlines